Axon Enterprise, Inc. shareholders lost money on November 6, 2026, when the stock fell sharply after the Company reduced its 2026 revenue outlook and reported third-quarter financial results below analyst consensus estimates. The Company lowered its full-year 2026 revenue guidance to $3.61-$3.63 billion, representing approximately 30% growth, down from its prior guidance range of $3.67-$3.725 billion, or 32%-34% growth. For the third quarter, Axon reported revenue of approximately $909 million against consensus estimates of $934-$938 million, and adjusted EPS of $1.72 against estimated ranges of $1.88-$1.91. Management explained that the lowered outlook resulted from removing roughly $200 million in bookings tied to three delayed Federal Dedrone deployments, which included a $130 million deployment expected in Q3 and two projects expected in Q4. This guidance reduction contrasted with prior management statements. On August 5, 2026, CFO Brittany Bagley stated, "We're raising our full-year revenue guidance to a range of 32%-34%, 200 basis points above our prior range of 30%-32%." Additionally, on September 16, 2026, the Company completed a $1 billion convertible notes offering after filing a Form FWP stating that it "continued to see strong adoption of its AI and counter-drone offerings." The investigation concerns whether Axon Enterprise, Inc. adequately disclosed potential timing delays and revenue risks regarding its Federal Dedrone deployments ahead of the November 5, 2026 guidance reduction.